Randomized phase II trial of seribantumab in combination with paclitaxel in patientswith advanced platinum-resistant or -refractory ovarian cancer
Articolo
Data di Pubblicazione:
2016
Citazione:
Randomized phase II trial of seribantumab in combination with paclitaxel in patientswith advanced platinum-resistant or -refractory ovarian cancer / J.F. Liu, I. Ray-Coquard, F. Selle, A.M. Poveda, D. Cibula, H. Hirte, F. Hilpert, F. Raspagliesi, L. Gladieff, P. Harter, S. Siena, J.M. del Campo, I. Tabah-Fisch, J. Pearlberg, V. Moyo, K. Riahi, R. Nering, W. Kubasek, B. Adiwijaya, A. Czibere, R.W. Naumann, R.L. Coleman, I. Vergote, G. MacBeath, E. Pujade-Lauraine. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 34:36(2016), pp. 4345-4353. [10.1200/JCO.2016.67.1891]
Abstract:
Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) -mediated ErbB3 signaling and inducing ErbB3 receptor downregulation. This open-label randomized phase II study evaluated progression-free survival (PFS) with seribantumab in combination with once-per-week paclitaxel compared with paclitaxel alone in patients with platinum-resistant or -refractory ovarian cancer. A key secondary objective was to determine if any of five prespecified biomarkers predicted benefit from seribantumab. Patients and Methods Patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer were randomly assigned at a ratio of two to one to receive seribantumab plus paclitaxel or paclitaxel alone. Patients underwent pretreatment core needle biopsy; archival tumor samples were also obtained to support biomarker analyses. Results A total of 223 patientswere randomly assigned (seribantumab plus paclitaxel, n = 140; paclitaxel alone, n = 83).Median PFS in the unselected intent-to-treat population was 3.75 months with seribantumab plus paclitaxel compared with 3.68 months with paclitaxel alone (hazard ratio [HR], 1.027; 95% CI, 0.741 to 1.425; P = .864). Among patients whose tumors had detectable HRG mRNA and low HER2 (n = 57 [38%] of 151with available biomarker data), increased treatment benefitwas observed in those receiving seribantumab plus paclitaxel compared with paclitaxel alone (PFS HR, 0.37; 95%CI, 0.18 to 0.76; P = .007). The HR in patients notmeeting these criteriawas 1.80 (95%CI, 1.08 to 2.98; P = .023). Conclusion The addition of seribantumab to paclitaxel did not result in improved PFS in unselected patients. Exploratory analyses suggest that detectable HRG and low HER2, biomarkers that link directly to the mechanism of action of seribantumab, identified patients who might benefit from this combination. Future clinical trials are needed to validate this finding and should preselect for HRG expression and focus on cancers with low HER2 levels.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome; Oncology; Cancer Research
Elenco autori:
J.F. Liu, I. Ray-Coquard, F. Selle, A.M. Poveda, D. Cibula, H. Hirte, F. Hilpert, F. Raspagliesi, L. Gladieff, P. Harter, S. Siena, J.M. del Campo, I. Tabah-Fisch, J. Pearlberg, V. Moyo, K. Riahi, R. Nering, W. Kubasek, B. Adiwijaya, A. Czibere, R.W. Naumann, R.L. Coleman, I. Vergote, G. Macbeath, E. Pujade-Lauraine
Link alla scheda completa: